Thursday, January 31, 2013

Reuters: Global Markets: Blackstone expects to cash in more on investments

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Blackstone expects to cash in more on investments
Jan 31st 2013, 21:36

By Greg Roumeliotis

NEW YORK | Thu Jan 31, 2013 4:36pm EST

NEW YORK (Reuters) - Blackstone Group LP (BX.N) reported a 43 percent rise in fourth-quarter profit on Thursday, capping what it called its best year as a publicly listed alternative asset manager, despite a lackluster performance by its flagship real estate business.

Blackstone's shares closed up 6.1 percent at $18.50 on the New York Stock Exchange. They had previously risen 11.9 percent this month, outperforming the S&P 500 Index .INX, which rose 5.3 percent.

Blackstone's private equity business made a strong comeback in 2012 on the back of higher fund valuations, rising 14.3 percent for the year, as markets rallied. Its real estate portfolio rose 14.4 percent, but earnings were roughly flat based on how the firm booked performance fees last year.

Real estate remained the largest earnings contributor even as private equity profits rose 86 percent in the fourth quarter.

Blackstone, whose investments include The Weather Channel, Pinnacle Foods and SeaWorld Parks & Entertainment, said economic net income (ENI), a measure of profitability that takes into account the mark-to-market valuation of its assets, was $670 million, up 43 percent from a year ago.

Blackstone, the first to report fourth-quarter results in a peer group that includes KKR & Co LP (KKR.N), Carlyle Group LP (CG.O) and Apollo Global Management LLC (APO.N), said earnings rose strongly in its private equity, hedge funds and credit units.

ENI in its real estate division was down 2 percent to $246 million. Private equity posted an 86 percent rise in ENI to $198 million, hedge funds a 163 percent rise to $82.7 million and credit a 96 percent rise to $107.2 million.

Overall, Blackstone's adjusted ENI was 59 cents per unit in the fourth quarter, topping an average estimate by analysts of 47 cents.

"The strong performance and realized gains coupled with another solid quarter for fundraising reaffirms our view that Blackstone's diversified alternative platform, undervalued future carried interest potential and strong secular flow trends all contribute to what we view as one of the more compelling long-term opportunities in the space," Barclay's analysts wrote in a note.

Distributable earnings, which show cash available to pay dividends, jumped 177 percent to $493.8 million in the fourth quarter as Blackstone took advantage of the buoyant equity and debt capital markets to divest more of its investments.

MORE REALIZATIONS

Among Blackstone's exits from investments in 2012 were an initial public offering of U.S. refiner PBF Energy Inc (PBF.N), valuing Blackstone's investment at 4.7 times what it paid, and further share sales of Team Health Holdings Inc (TMH.N), which averaged a value of 3.9 times Blackstone's investment.

Blackstone also sold its Sunwest senior living business in the fourth quarter, a $220 million investment, making 2.4 times its money in just two years.

"If we did that with every piece of real estate, we would be managing most of the money in the world. But it does happen, and it isn't just an odd outcome," Chief Executive Stephen Schwarzman said on a call with analysts.

In private equity, Blackstone returned $3.5 billion to investors in 2012 at an average 2.1 times their money. Across all its funds, Blackstone said it returned $18 billion to its investors. In real estate, it returned $3.7 billion.

"2013 should be a higher year for realizations in general... and 2014 should be another good year. The portfolio that is maturing the fastest and into which there is the best bid to sell, so to speak, is real estate at this point," Blackstone's President Tony James told reporters on a conference call.

The lack of building and commercial real estate offers an opportunity to sell for a good price even in an economy that is not very strong, James added.

Total assets under management were $210.2 billion as of the end of December, up from $204.6 billion at the end of the third quarter. Fee-earning assets under management were $167.9 billion at the end of December, down from $168.6 billion at the end of the third quarter.

In the fourth quarter, Blackstone raised $3.3 billion for its new rescue lending fund and said it expected it would total $4 billion to $5 billion this year.

Blackstone's undrawn capital, so-called "dry powder" available for deals, was $35 billion at the end of the year. Private equity had $15.7 billion in dry powder and real estate had $11 billion.

Blackstone's financial advisory arm had a record level of revenue in the fourth quarter as some companies and financial investors rushed to close deals by the end of the year to avoid higher taxes. But this was insufficient to offset a 21 percent drop in profits for the year in that business.

New York-based Blackstone declared a quarterly distribution of 42 cents per common unit. It said it intends to increase its base quarterly distribution to 12 cents per unit in 2013, up from 10 cents per unit.

Founded by Schwarzman and Peter Peterson in 1985 as a private equity firm, Blackstone went public in 2007 and has become more of a real estate group in recent years, as this franchise has come to dominate its earnings.

(Reporting by Greg Roumeliotis in New York; Editing by John Wallace, Nick Zieminski, Jim Marshall and Leslie Gevirtz)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Under Armour profit tops Wall Street for ninth straight time

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Under Armour profit tops Wall Street for ninth straight time
Jan 31st 2013, 20:55

Thu Jan 31, 2013 3:55pm EST

(Reuters) - Athletic apparel maker Under Armour Inc (UA.N) reported a higher-than-expected quarterly profit for the ninth straight time as customers scooped up its water-resistant clothing and new footwear products during the holiday season.

The company's shares rose as much as 8 percent on Thursday.

The maker of ColdBlack and the Armour Bra also forecast full-year revenue of between $2.20 billion and $2.22 billion, while analysts on average were expecting $2.22 billion.

"Top-line trends remain solid moving into full-year 2012. Apparel growth remains resilient with the 13th straight quarter of over 20 percent growth in the fourth quarter," Susquehanna Financial Group analyst Christopher Svezia said in a note.

Under Armour's apparel revenue rose 25 percent to $405 million in the fourth quarter, while footwear revenue jumped 43 percent to $45 million.

Oppenheimer & Co analyst Pamela Quintiliano said going forward the company's aggressive approach in marketing and new specialty store design should attract new and lapsed customers.

Under Armour, which is known for its clothing that draws sweat away from the body, said profit rose to $50.1 million, or 47 cents per share, for the quarter ended December 31 from $32.6 million, or 31 cents per share, a year earlier.

Revenue jumped 25 percent to $505.9 million.

Analysts on average had expected a profit of 46 cents per share on revenue of $497.7 million, according to Thomson Reuters I/B/E/S.

The company's shares were up 6 percent at $51.11 in late-afternoon trading on the New York Stock Exchange. They touched a seven-week high of $51.92 earlier.

(Reporting By Siddharth Cavale and Arpita Mukherjee and Maria Ajit Thomas in Bangalore; Editing by Maju Samuel)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: BlackBerry shares slide as new devices face uphill battle

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
BlackBerry shares slide as new devices face uphill battle
Jan 31st 2013, 18:52

Ben Stephens (R), a Blackberry sales manager demonstrates a new Blackberry Z10 to prospective customer Shevek (C), as store manager Alejandra Escobar watches at a branch of UK retailer Phones 4U in central London, January 31, 2013. Blackberry's new Z10 model went on sale in the UK today. Research In Motion Ltd's glitzy unveiling of the long-delayed line of BlackBerry smartphones on Wednesday and a new corporate name failed to impress Wall Street analysts, with at least three downgrading the company's stock. REUTERS/Andrew Winning

1 of 6. Ben Stephens (R), a Blackberry sales manager demonstrates a new Blackberry Z10 to prospective customer Shevek (C), as store manager Alejandra Escobar watches at a branch of UK retailer Phones 4U in central London, January 31, 2013. Blackberry's new Z10 model went on sale in the UK today. Research In Motion Ltd's glitzy unveiling of the long-delayed line of BlackBerry smartphones on Wednesday and a new corporate name failed to impress Wall Street analysts, with at least three downgrading the company's stock.

Credit: Reuters/Andrew Winning

By Euan Rocha

NEW YORK | Thu Jan 31, 2013 1:52pm EST

NEW YORK (Reuters) - The afterglow of Research In Motion Ltd's BlackBerry 10 unveiling faded on Thursday as a flurry of lukewarm reviews signaled the company's struggle to regain momentum in the hyper-competitive smartphone market was just beginning.

Shares of BlackBerry, RIM's new corporate name, fell almost 10 percent early on Thursday, after a 12 percent decline the previous day, as some tech analysts questioned whether the new BB10 devices the company launched on Wednesday were the sure-fire hit that BlackBerry needs to get back into the game.

While New York Times reviewer David Pogue gushed that BlackBerry's new Z10 model is "lovely, fast and efficient, bristling with fresh, useful ideas," other reviewers were more tentative in their appraisals.

"The problem with the Z10 is that it doesn't necessarily do anything better than any of its competition," said Joshua Topolsky of technology news website the Verge. "No one could argue that there's a 'killer app' here. Something that makes you want or need this phone because it can do what no other phone can do. That's not the case."

Such lukewarm reviews - combined with disappointment around a later-than-expected and still unspecified date for the U.S. sales debut - spooked investors and prompted analysts to cut their price targets and forecasts.

BlackBerry, which is making a big push to win back the all-important U.S. market with a Super Bowl ad this weekend, said the new Z10 touch-screen device would not go on sale in the United States until sometime in mid-March, saying U.S. carriers need more time to test the model.

"The shine from the Super Bowl ad will be a fading memory by the time U.S. customers can buy in March," said TD Securities analyst Scott Penner, who has a "hold" rating on the stock.

Samsung Electronics Co may also steal some of BlackBerry's thunder as buzz around its Galaxy IV device heats up before the Z10 hits U.S. store shelves, Penner pointed out.

Making matters worse for BlackBerry, it has been not been very specific about how soon it will be before many of its most loyal fans across the globe can get their hands on the Q10 - its new qwerty keyboard model. The company has only said that it aims to release this version of the smartphone in April.

"While later-than-expected availability of the Z10 and Q10 devices shouldn't impact the longer-term potential success of the BB10 platform, we believe it does mitigate one of the near-term catalysts for the stock," said Paradigm Capital analyst Gabriel Leung, who trimmed his price target on the stock to $16 from $19.50.

RIM shares were down 5.2 percent at $13.05 at 12:15 EST (1715 GMT) Thursday on the Nasdaq, while its Toronto-listed shares were down 5.8 percent at C$13.06.

HIGH-END TARGET MARKETS

Initially at least, the BlackBerry 10 is aimed squarely at the North American and European markets, where consumers and businesses alike are eager to snap up high-end devices.

In countries like India - the world's second-largest mobile phone market - the premium cost of the new Z10 handset will restrict sales. Even so, the new device, which sources said will likely enter the key Indian market in mid-February, could help the Canadian company compete with premium rivals such as Apple Inc there.

"The Z10 launched yesterday is obviously a high-end product and India is not a market at that price point," said Anshul Gupta, industry analyst at Gartner, a technology advisory firm.

BlackBerry is the third-largest smartphone player in India after Samsung and Nokia, due mainly to its low-cost handsets that allow young people to communicate for free on its BlackBerry Messaging Service.

RIM launched its first BlackBerry more than a decade ago, as a way for busy executives to stay in touch with both clients and their offices.

BlackBerry quickly cornered the market for secure corporate and government emails, but its star has faded in recent years as competition heated up and RIM failed to keep pace.

The BlackBerry is now an also-ran in the race for market share, with a 3.4 percent global showing in the fourth quarter, down from some 20 percent three years ago.

RIM's new smartphones are considered a make-or-break attempt to save the company and claw back market share that it has lost to the likes of Apple's iPhone and Samsung's Galaxy devices.

"BlackBerry has demonstrated truly unique software innovation within BB10," wrote Raymond James analyst Steven Li in a note to clients. "However, convincing the many BlackBerry users who have abandoned the platform for iOS and Android over the last few years to return will be a difficult challenge as Microsoft and Nokia can surely attest to."

(Editing by Frank McGurty; and Peter Galloway)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Tri Pointe Homes jumps 15 percent in market debut

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Tri Pointe Homes jumps 15 percent in market debut
Jan 31st 2013, 15:24

Thu Jan 31, 2013 10:24am EST

(Reuters) - Shares of Tri Pointe Homes (TPH.N), the first U.S. homebuilder to go public in almost a decade, opened up 15 percent in their market debut after the company priced its initial public offering (IPO) above the expected price range.

The stock opened at $19.56, valuing the company at $618 million. About 4.5 million shares had exchanged hands on the New York Stock Exchange by 1000 ET.

The company had said earlier on Thursday that it priced the IPO of 13.7 million shares - 43 percent of its outstanding shares - at $17 per share, raising about $233 million.

Majority shareholder and Chairman Barry Sternlicht will retain a 45.4 percent stake in the Irvine, California-based company, according to a filing.

Tri Pointe is aiming to take advantage of a recovery in the housing market six years after it fell into a deep rut that preceded the worst recession in the United States since the Great Depression.

Smaller, privately held homebuilders were hit badly when the housing bubble burst in 2007, draining the funds that they now need to buy land and build new homes.

Fellow homebuilder, Taylor Morrison Home Corp also filed with U.S. regulators in December to raise up to $250 million in an IPO.

By going public, these smaller companies are trying to raise cash and meet the burgeoning demand for homes in the United States, a market in which they compete with large established players such as D.R. Horton Inc (DHI.N), Lennar Corp (LEN.N), PulteGroup Inc (PHM.N) and Toll Brothers Inc (TOL.N).

Citigroup, Deutsche Bank Securities and FBR are the lead underwriters for the offering.

(Reporting by Tanya Agrawal and Aman Shah in Bangalore; Editing by Roshni Menon)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Conoco shares off 5 percent, output forecast disappoints

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Conoco shares off 5 percent, output forecast disappoints
Jan 31st 2013, 15:20

  • Tweet
  • Share this
  • Email
  • Print
Smoke is released into the sky at the ConocoPhillips oil refinery in San Pedro, California March 24, 2012. REUTERS/Bret Hartman

Smoke is released into the sky at the ConocoPhillips oil refinery in San Pedro, California March 24, 2012.

Credit: Reuters/Bret Hartman

Thu Jan 31, 2013 10:20am EST

(Reuters) - ConocoPhillips (COP.N) shares fell over 5 percent on Thursday, a day after the U.S. oil and natural gas company issued a production forecast that fell short of some Wall Street expectations.

Conoco said on Wednesday it sees full-year 2013 production of 1.475 million to 1.525 million barrels oil equivalent (boe) per day.

Analysts at Houston energy investment bank Tudor Pickering Holt characterized Conoco's production forecast as "negative." Tudor Pickering had expected full-year output of 1.531 million boe per day, it said in a note to clients.

Shares of Conoco dropped $3.18 to $57.91 in morning New York Stock Exchange trading.

(Reporting By Anna Driver; Editing by Gerald E. McCormick)

Related Quotes and News

Company

Price

Related News

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Zimmer posts slightly weaker earnings, shares dip

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Zimmer posts slightly weaker earnings, shares dip
Jan 31st 2013, 15:37

Thu Jan 31, 2013 10:37am EST

(Reuters) - Zimmer Holdings Inc (ZMH.N) on Thursday reported slightly weaker quarterly net earnings as the orthopedic device maker continued to trim costs.

The maker of orthopedic implants, surgical instruments, spinal and dental devices also provided an outlook for the full year that was within Wall Street's expectations, though some analysts were skeptical.

Shares dipped $1.27 to $73.16 in early trading on the New York Stock Exchange, following a 20 percent advance over the past 6 months.

Fourth-quarter net earnings were $152.8 million or 88 cents per share, compared with $156.6 million, or 87 cents per share. There were fewer shares outstanding this year.

Excluding items, adjusted earnings were $1.51, which beat the average estimate on Wall Street of $1.49, according to Thomson Reuters I/B/E/S.

Sales were $1.18 billion in the quarter, up from $1.17 billion a year before.

Zimmer said it expected full year earnings, excluding items, to be between $5.65 and $5.85 per share, bracketing the Thomson Reuters I/B/E/S estimate of $5.73.

The company said it expects sales to rise 2.5 percent to 4.5 percent in 2013, which also meets the Thomson Reuters I/B/E/S sales estimate of $4.63 billion.

Zimmer executives told analysts on a conference call that they should focus on the midpoint of the outlook.

David Roman, an analyst with Goldman Sachs, said the forecast implies improving markets, an assumption with which he agrees, but also implies strong adoption of its new products.

"We question this," he said in a research note to clients.

"It seems early to conclude that new products can have a material impact on the revenue outlook. The ramp will likely be slow, as the company trains physicians, gets instrument sets into the field, and secures hospital contracts," said Roman, who has a "neutral" rating on the stock.

"Execution also needs to improve, as we would have expected better results out of Zimmer given the acceleration in overall orthopedic volumes this quarter," he added.

(Reporting By Debra Sherman; Editing by Gerald E. McCormick, Nick Zieminski and Kenneth Barry)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Celsion plunges 80 percent as liver cancer therapy fails trial

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Celsion plunges 80 percent as liver cancer therapy fails trial
Jan 31st 2013, 16:36

Thu Jan 31, 2013 11:36am EST

(Reuters) - Celsion Corp shares plunged by more than 80 percent after a late-stage study of the company's experimental liver cancer treatment ThermoDox failed to meet the main goal of increasing patients' survival without worsening their cancer.

The stock fell to a low of $1.41 before recovering slightly to trade at $1.46 on heavy volume on the Nasdaq on Thursday.

"I don't believe the data will support (marketing) registration in any of the major markets," Celsion Chief Executive Michael Tardugno said on a conference call.

The trial, named HEAT, consisted of 701 patients across 11 countries and was designed to show a 33 percent improvement in progression-free survival.

Celsion said it was conducting additional analyses of data from the trial to assess the future value of ThermoDox.

Patients on the control arm performed about 20 percent better than expected whereas those on ThermoDox performed worse than anticipated, Roth Capital Partners analyst Joseph Pantginis said, quoting the company.

"We are disappointed by the failure of the HEAT study and we highlight the increased risk around the company's pipeline which is driven by ThermoDox," he said.

ThermoDox is also being tested in mid-stage studies as a drug-delivery method for breast and colorectal cancers.

Celsion CEO Tardugno said the company will continue enrolling patients in the mid-stage breast cancer study.

ThermoDox utilizes a liposome -- a tiny bubble composed of lipids -- as a vehicle to transport a commonly used chemotherapy drug called doxorubicin, directly to the tumor.

Localized heat releases doxorubicin, depositing it in and around the tumor, maximizing the effect of the medication.

The liver-cancer study compared the HEAT results against patients treated with a procedure where tumors are destroyed using electricity, otherwise called radiofrequency ablation.

Pantginis downgraded Celsion's rating to "neutral" from "buy" and slashed his price target on the stock to $1.70 from $10, saying the target is now based solely on the mid-stage study of ThermoDox in breast cancer.

Celsion said it had sufficient cash to cover its expenses well into 2014. It has unaudited cash and investments of about $27 million.

CEO Tardugno said the company will review its colorectal cancer trial in the context of the HEAT results and then decide on whether to continue with the study.

(Reporting By Pallavi Ail in Bangalore; Editing by Roshni Menon and Sreejiraj Eluvangal)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Vanda to stop developing anti-depressant, shares slip

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Vanda to stop developing anti-depressant, shares slip
Jan 31st 2013, 14:13

Thu Jan 31, 2013 9:13am EST

(Reuters) - Vanda Pharmaceuticals Inc said it would stop developing its experimental drug for major depressive disorder after it failed to meet the main goal of improving symptoms in patients in a clinical trial, sending its shares down about 8 percent.

The company said patients treated with the drug tasimelteon and those on a placebo showed about a 40 percent reduction in symptoms, based on a standard scale that measures severity of depression.

The trial, named Magellan, enrolled 507 patients in 43 sites in the United States, and was comparing a 20mg dose of the drug with a placebo.

Major depressive disorder is one of the most common mental disorders in the United States and affects about 14.8 million American adults, according to the National Institute of Mental Health.

The company is also studying tasimelteon as a treatment for a rare sleep disorder, called "non-24-hour disorder" - a condition in which a person's body clock does not automatically set to the 24-hour day and affects a majority of blind people.

"Tasimelteon's application in the treatment of blind individuals with Non-24 remains our top priority as we pursue our planned NDA submission this year," Vanda CEO Mihael Polymeropoulos said in a statement.

Vanda said last week that tasimelteon proved effective in a second late-stage trial for non-24-hour disorder and that it planned to apply for a U.S. approval for the drug in mid-2013.

Vanda has an approved schizophrenia drug called Fanapt that is sold in partnership with Novartis in the United States. It also has an experimental drug for alcohol dependence, called VLY-686, that it licensed from Eli Lilly.

Vanda's stock was trading at $4.00 before the bell. It closed at $4.34 on Wednesday on the Nasdaq. It has gained 5 percent since the company reported data for non-24-hour disorder last week.

(Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Lender Processing says to settle state inquiries for $127 million

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Lender Processing says to settle state inquiries for $127 million
Jan 31st 2013, 14:34

Thu Jan 31, 2013 9:34am EST

(Reuters) - Lender Processing Services Inc said it will pay $127 million to settle inquiries related to some of its signing and notarization practices.

Shares of the company rose more than 8 percent to $24.25 in early trading Thursday on the New York Stock Exchange.

The mortgage service provider said it had entered into settlements with attorneys general of 46 states and the district of Columbia.

LPS said it increased its legal and regulatory reserve for the quarter ended December 31 by $48 million. The company is scheduled to report fourth-quarter results on February 7.

LPS had previously settled similar inquiries with Missouri, Delaware and Colorado and Thursday's settlement leaves the complaint filed by Nevada as the only unresolved inquiry.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Elizabeth Arden cuts FY forecast, shares slump 20 percent

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Elizabeth Arden cuts FY forecast, shares slump 20 percent
Jan 31st 2013, 14:59

Thu Jan 31, 2013 9:59am EST

(Reuters) - Cosmetics maker Elizabeth Arden Inc (RDEN.O) cut its full-year forecast after reporting lower-than-expected quarterly results due to weak sales at department stores and what it called a "major mass retail account" during the holiday season.

The company's shares fell 20 percent to $36.62 in early trading on the Nasdaq on Thursday.

Arden, which holds fragrance licenses for brands from True Religion Apparel and for hip-hop star Nicki Minaj and Justin Bieber, lowered its full-year earnings forecast to between $2.30 and $2.50 per share from between $2.55 and $2.70 per share. Analysts were looking $2.66 on average, according to Thomson Reuters I/B/E/S.

It now expects sales to grow by 9 to 11 percent during the year, and not by the 13.5 to 15 percent forecast earlier. The projection implies a revenue of $1.35 billion to $1.37 billion, below the $1.42 billion analysts estimated.

The company has been trying to make its namesake brand more upscale by revamping its cosmetics line and adding more celebrity fragrances, and was well positioned going into the holiday season, Suntrust Robinson Humphrey analyst Bill Chappell said in a note.

Nevertheless, he was surprised that the results didn't beat expectations.

"We now wonder whether it is simply too early for the cosmetics restage to make an impact on overall results," Chappell said, maintaining his "neutral" rating on the stock.

The company's net income rose to $48.1 million, or 1.58 per share, from $42.4 million, or $1.42 per share, a year earlier.

Excluding one-time items, Elizabeth Arden reported earnings of $1.58 per share, missing the $1.63 per share analysts expected.

Revenue rose 9 percent to $468 million, well below the average analyst estimate of $492.3 million.

(Reporting by Siddharth Cavale in Bangalore and Phil Wahba in New York; Editing by Sreejiraj Eluvangal)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Facebook slumps as mobile ad growth fails to impress

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Facebook slumps as mobile ad growth fails to impress
Jan 31st 2013, 12:56

  • Tweet
  • Share this
  • Email
  • Print
The Facebook logo is pictured at the Facebook headquarters in Menlo Park, California January 29, 2013. REUTERS/Robert Galbraith

The Facebook logo is pictured at the Facebook headquarters in Menlo Park, California January 29, 2013.

Credit: Reuters/Robert Galbraith

Thu Jan 31, 2013 7:56am EST

(Reuters) - Shares of Facebook Inc were set to open 7 percent lower on Thursday as a surge in fourth-quarter mobile advertising revenue failed to live up to Wall Street's high expectations.

Three brokerages downgraded the stock of the No. 1 social network, which has struggled to develop a full-fledged mobile advertising business.

Facebook has long established itself as one of the most important websites, but investors have worried that until the company's mobile advertising strategy takes off, revenue growth will remain shaky.

The company reported a better-than-expected fourth-quarter profit on Wednesday and said its mobile advertising revenue doubled to $306 million, suggesting it was making inroads into handheld devices such as smartphones and tablets.

Investors were looking for at least $350 million in mobile advertising revenue, Piper Jaffray analyst Gene Munster said in a note to clients.

"While the trajectory of mobile growth may not be as steep as some investors were hoping, the theme of mobile as the future of Facebook remains intact," he said.

BMO Capital Markets analyst Daniel Salmon, who downgraded the stock to "market perform" from "outperform", however said Facebook's 2013 stock performance would not be dictated by its ability to generate mobile ad dollars.

He said new catalysts were necessary to drive Facebook's stock price up.

Facebook's stock, which has lost over a quarter of its value since its botched debut in May, were down at $29.08 in premarket trading. The shares closed at $31.24 on the Nasdaq on Wednesday.

(Reporting by Neha Alawadhi in Bangalore; Editing by Saumyadeb Chakrabarty)

Related Quotes and News

Company

Price

Related News

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Fiat Industrial cuts 2013 targets, shares fall

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Fiat Industrial cuts 2013 targets, shares fall
Jan 31st 2013, 11:33

By Jennifer Clark and Stefano Rebaudo

MILAN | Thu Jan 31, 2013 6:33am EST

MILAN (Reuters) - Italian truck and tractor maker Fiat Industrial (FI.MI) has cut its 2013 targets, after truck sales at its Iveco unit fell 6.7 percent in weak European and Latin American markets last year, forcing it to adjust a business plan set out in 2010.

"The new target for trading profit next year is below the previous business plan, which however is very old," said Marco Cristofori, an analyst at Centrobanca. "The analyst consensus is more or less in line with the new targets."

At 6:20 a.m. ET, the shares were down 2 percent at 9.28 euros.

The company said it saw a trading margin on sales of between 8.3 percent and 8.5 percent in 2013, which works out to a trading profit of between 2.2 and 2.3 billion euros.

The previous target was a trading profit of 2.5 to 2.8 billion euros, set in 2010.

Analysts were forecasting a trading profit of 2.29 billion euros for 2013, according to a consensus compiled by the company.

The new sales forecast for 2013 is about 27 billion euros, in line with the earlier business plan for 2011 through 2014.

The company sees its debt at between 1.1 billion euros and 1.4 billion this year, a touch lower than the 1.64 billion at the end of 2012 but well above the analysts' consensus of 795 million.

It said its fourth-quarter trading profit rose to 438 million euros, on the back of strong performance of its agricultural unit CNH (CNH.N), where sales rose 15.5 percent to 16.0 billion euros.

"Solid global demand for agricultural equipment more than offset the negative effects of the more difficult trading conditions in the construction equipment segment," the company said in a statement.

Fiat Industrial said it will pay a dividend of 0.225 euros per share.

(Reporting by Jennifer Clark and Stefano Rebaudo; Editing by Stephen Jewkes and David Holmes)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Time Warner Cable adds fewer Internet users; shares dip

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Time Warner Cable adds fewer Internet users; shares dip
Jan 31st 2013, 13:13

The Time Warner Cable office is shown in Carlsbad, California November 5, 2012. REUTERS/Mike Blake

The Time Warner Cable office is shown in Carlsbad, California November 5, 2012.

Credit: Reuters/Mike Blake

By Liana B. Baker and Supantha Mukherjee

Thu Jan 31, 2013 8:13am EST

(Reuters) - Time Warner Cable Inc, the second-largest U.S. cable operator, reported a fourth-quarter profit that beat analysts' estimates but added fewer high-speed Internet users than analysts had forecast.

Time Warner Cable and larger rival Comcast Corp have increasingly relied on Internet services for growth as they continue to shed cable TV subscribers.

Shares of Time Warner Cable fell nearly 3 percent in premarket trading.

On Monday, Time Warner said it would carry the new Los Angeles Dodgers channel, outbidding Fox Sports, which held the rights to show Dodgers games for more than a decade. Analysts said the deal, about which Time Warner Cable hasn't revealed financial details, would be in focus during a conference call Thursday.

"People want to know about the cost, the logic behind the regional sports networks and if there are going to be more costs associated with this," said Macquarie analyst Amy Yong said.

In 2011, the agreed to a $3 billion, 20-year deal to carry Los Angeles Lakers basketball games on its Time Warner Cable Sports channel.

Time Warner Cable lost 129,000 video subscribers, lower than the estimated loss of 134,000 subscribers, according to StreetAccount data.

The cable company added 75,000 high-speed data subscribers in its residential services unit, compared with analysts' average expectation of 109,000 subscriber additions, according to StreetAccount.

"Net additions across the board for video, Internet and voice were weak. Competition still remains pretty intense and housing still remains inconclusive," Yong said.

The company said average monthly video programming costs per video subscriber increased 5.1 percent to $31.28, mainly driven by contractual rate increases and paying to carry new networks.

The cable provider has been a vocal critic of rising programming costs and has signed long-term sports contracts and said it would manage costs better.

Time Warner said residential high-speed data revenue for the quarter rose 17.2 percent due to price increases and more subscribers opting for higher-priced services.

The company raised its regular quarterly dividend by 16 percent to 65 cents per share.

Net income attributable to the company for the fourth quarter fell to $513 million, or $1.68 per share, from $564 million, or $1.75 per share, a year earlier.

Excluding items, the company earned $1.57 per share on 10 percent higher revenue of $5.49 billion.

Analysts expected earnings of $1.55 per share, excluding items, on revenue of $5.5 billion, according to Thomson Reuters I/B/E/S.

(Reporting by Liana Baker in New York and Supantha Mukherjee in Bangalore; Editing by Saumyadeb Chakrabarty and Bernadette Baum)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: New AstraZeneca CEO plans to invest through tough year

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
New AstraZeneca CEO plans to invest through tough year
Jan 31st 2013, 12:31

By Ben Hirschler

LONDON | Thu Jan 31, 2013 7:31am EST

LONDON (Reuters) - AstraZeneca's (AZN.L) new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.

Chief Executive Pascal Soriot forecast a mid-to-high single digit percentage fall in revenue this year, as patent expiries continue to erode business, with earnings declining "significantly more" due to increased operating costs.

The 2013 outlook was worse than the fall of around 3 percent in sales that analysts had been expecting, and shares in the group slumped 5.4 percent by 6:50 a.m. ET on Thursday.

A decision to keep share buybacks on hold and not increase the dividend for the first time in a decade added to the market's disappointment.

Soriot also withdrew mid-term planning assumptions for profit margin and revenue that had been set by previous management, increasing his freedom to pursue a strategy of investing for future growth.

Analysts at Citigroup said he appeared to be setting the scene for doing new deals - something the market has speculated about intensely in recent months.

"We will be open to more disruptive acquisitions, larger acquisitions if they make sense," Soriot told reporters.

But he added: "You have to consider the likelihood of that is lower because I don't think we need a large-scale acquisition to succeed."

Soriot said any deals he struck would complement increased investment in five existing growth areas - the new heart drug Brilinta, emerging markets, diabetes care, respiratory medicine and Japan.

Faced with loss of exclusivity on once best-selling medicines and a thin pipeline of new drugs, AstraZeneca needs to consider bold moves to get back on its feet.

Yet Soriot has to tread carefully when it comes to spending if he is to avoid upsetting investors who own the stock as an income play, given its near 6 percent dividend yield.

He is due to set out his strategy in detail during a keenly-awaited investor day on March 21 in New York.

Many analysts expect he will follow the lead set by Bristol-Myers Squibb (BMY.N), which has used what it calls a "string of pearls" strategy to boost revenue through small or mid-sized purchases. But there has also been talk of a $20 billion-plus deal, such as buying Shire (SHP.L).

Results for the last quarter of 2012, which came better than expected, took second place to the tough outlook for 2013.

Fourth-quarter sales fell 16 percent to $7.28 billion, generating core earnings, which exclude certain items, down 3 percent at $1.56 per share. The slower decline in earnings reflected lower costs and a favorable tax adjustment.

Analysts had, on average, forecast sales of $7.20 billion and earnings of $1.35 per share, according to Thomson Reuters I/B/E/S. Stripping out the tax effect, EPS was broadly in line.

BIG HITS TO COME

AstraZeneca is not alone in facing big patent losses.

But while rivals such as GlaxoSmithKline (GSK.L) and Sanofi (SASY.PA) are past the worst, AstraZeneca's biggest losses are to come, with Nexium for stomach acid and cholesterol fighter Crestor losing U.S. protection in 2014 and 2016 respectively.

As a pure pharmaceuticals group, without the cushion of alternative revenue streams found at more diversified rivals, AstraZeneca is particularly exposed to patent losses on key prescription drugs.

Short-term wins from its new drug pipeline look unlikely, with expectations for experimental rheumatoid arthritis drug fostamatinib dwindling after disappointing clinical trial results last month.

One established medicine that may surprise on the upside is diabetes drug Onglyza, which is marketed with Bristol-Myers and could potentially show a heart benefit in a clinical study that will report later this year.

Heart drug Brilinta, which had been viewed as big winner initially, continued to struggle to generate sales in the three months to end-December, with sales totalling $38 million.

AstraZeneca shares have gained ground in recent months but the stock remains the laggard of the global pharmaceutical sector, trading on around 8.6 times expected earnings, a 30 percent discount to large British rival GSK.

The group has already slashed thousands of jobs to cut costs in recent years, and two weeks ago Soriot removed the heads of both research and worldwide sales.

(Editing by Dan Lalor and Jane Merriman)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

 
Great HTML Templates from easytemplates.com.